上市公司名称：西藏多瑞医药股份有限公司 西藏多瑞医药股份有限公司 要约收购报告书摘要 股票上市地点：深圳证券交易所 股票简称：多瑞医药 股票代码：301075 收购人一：王庆太 住所/通讯地址：河北省邢台市广宗县经济开发区创业大道南段东侧天王科技园 收购人二：曹晓兵 住所/通讯地址：北京市石景山区启迪香山 A 座 238 室 收购人一致行动人：崔子浩 住所/通讯地址：河北省邢台市任泽区荣御新天地 45 号楼 签署日期：二〇二五年十月 1 西藏多瑞医药股份有限公司 要约收购报告书摘要 重要声明 本要约收购报告书摘要的目的仅为向社会公众投资者提供本次要约收购的 简要情况，投资者在做出是否预受要约的决定之前，应当仔细阅读要约收购报告 书全文，并以此作为投资决定的依据。 要约收购报告书全文将刊登于深圳证券交易所网站(http://www.szse.com.cn)。 2 西藏多瑞医药股份有限公司 要约收购报告书摘要 特别提示 本部分所述的词语或简称与本报告书摘要"释义"部分所定义的词语或简称 具有相同的涵义。 1、根据 2025 年 10 月，西藏嘉康、舟山清畅与王庆太、崔子浩、曹晓兵， 以及邓勇签订的《股份转让协议》 ...

国金证券股份有限公司（以下简称"国金证券"）作为本次王庆太、曹晓兵 （以下简称"收购人"）及崔子浩（以下简称"收购人一致行动人"）要约收购西 藏多瑞医药股份有限公司（以下简称"多瑞医药"）的财务顾问，国金证券对收购 人本次要约收购发表如下结论性意见： "本财务顾问认为，收购人及其一致行动人本次要约收购符合《中华人民共 和国证券法》《上市公司收购管理办法》等法律法规的规定，具备收购多瑞医药 的主体资格，不存在《上市公司收购管理办法》第六条规定的不得收购上市公司 的情形。收购人对履行要约收购义务所需资金进行了稳妥的安排，收购人具备要 约收购实力和资金支付能力，具备履行本次要约收购的义务的能力。 本次要约收购人不存在未披露的一致行动人；除本次交易外，收购人于要约 收购报告书摘要公告前 6 个月未通过其他方式取得多瑞医药股份，不存在其他支 付安排，要约价格具有合理性。" 本财务顾问同意收购人在《西藏多瑞医药股份有限公司要约收购报告书摘 要》中引用上述财务顾问意见。 国金证券股份有限公司关于 《西藏多瑞医药股份有限公司要约收购报告书摘要》 之财务顾问意见 致：王庆太、曹晓兵、崔子浩 （本页无正文，为国金证券股份有限公司 ...

之 财务顾问核查意见 国金证券股份有限公司 关于 西藏多瑞医药股份有限公司 详式权益变动报告书 财务顾问 （成都市青羊区东城根上街 95 号） 二〇二五年十月 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购管 理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购 报告书》等法律法规和规范性文件的规定，国金证券股份有限公司（以下简称"本 财务顾问"）按照证券行业公认的行业标准、道德规范，本着诚实信用、勤勉尽 责的态度，对本次权益变动的相关情况和资料进行了核查，对信息披露义务人出 具的《西藏多瑞医药股份有限公司详式权益变动报告书》所披露的内容出具核查 意见，以供投资者和有关各方参考。 为此，本财务顾问特作如下声明： 1、本财务顾问所依据的有关资料由信息披露义务人提供。信息披露义务人 已向本财务顾问保证，其所提供的出具本核查意见所依据的所有文件和材料是真 实、准确、完整、及时的，不存在任何重大遗漏、虚假记载或误导性陈述，并对 其真实性、准确性、完整性和合法性负责； 2、本财务顾问已按照规 ...

中信证券股份有限公司 关于西藏多瑞医药股份有限公司 使用部分超募资金永久补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为西藏 多瑞医药股份有限公司（以下简称"多瑞医药"或"公司"）首次公开发行股票 并在深圳证券交易所创业板上市的保荐机构，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》和《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定，就多瑞医药使用部分超募 资金永久补充流动资金的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意西藏多瑞医药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2760 号）同意注册，多瑞医药首次 公开发行人民币普通股（A 股）股票 2,000.00 万股，每股面值 1.00 元，每股发 行价格为人民币 27.27 元，募集资金总额为人民币 54,540.00 万元，扣除相关发 行费用后实际募集资金净额为人民币 48,204.97 万元。上述募集资金到位情况经 天健会计师事务所（特殊普通合伙）进行了审验，并出具了《验资报告》（天健 验〔 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-083 西藏多瑞医药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）第二届董事会第 二十三次会议决定于2025年10月30日召开2025年第一次临时股东大 会。现将会议有关事项公告如下： 一、召开本次会议的基本情况 1、会议届次：2025年第一次临时股东大会 （2）网络投票时间：2025年10月30日（星期四） 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年10月30日09:15-09:25，09:30-11:30和13:00-15:00； 1 通过深圳证券交易所互联网系统（http://wltp.cninfo.com.cn）投票 的具体时间为：2025年10月30日09:15-15:00的任意时间。 5、会议召开方式：本次会议采取现场表决与网络投票相结合的 方式召开。 2、会议召集人：公司董事会 3、会议召开的合法、合规性：公司第二届董事会第二十三次会 议审议通过关于召开 ...

西藏多瑞医药股份有限公司 监事会关于第二届监事会第二十二次会议相关事项的监事会意见 根据《中华人民共和国公司法》《深圳证券交易所创业板股票上 市规则》《上市公司自律监管指引第 2 号——创业板上市公司规范运 作》《西藏多瑞医药股份有限公司章程》《西藏多瑞医药股份有限公司 监事会议事规则》的相关规定，监事会全体监事在认真检查和审核了 相关文件资料的基础上，就西藏多瑞医药股份有限公司（以下简称"公 司"）第二届监事会第二十二次会议相关事项发表如下监事会意见： 一、《关于向控股子公司增加担保额度的议案》的监事会意见 （本页无正文，为西藏多瑞医药股份有限公司关于第二届监事会第二 十二次会议相关事项的监事会意见签字页） 监事：赵宏伟_________ 王 堂_________ 周佳丽_________ 2025 年 10 月 13 日 监事会认为：公司本次向控股子公司增加担保额度，有利于其生 产经营，符合公司的发展要求，不存在损害公司利益的行为。本次担 保对象为公司控股子公司，公司能够对其经营进行有效监控与管理， 被担保对象的主体资格、资信状况及对外担保的审批程序符合《深圳 证券交易所创业板股票上市规则》《上市公司自律 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-077 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 四、 投资风险分析及风险控制措施 公司进行现金管理购买的产品属于安全性高的投资品种，但不排 除该项投资受到市场波动的影响。针对可能发生的收益风险，公司制 定如下措施： 1、在确保不影响公司正常生产经营的基础上，根据公司闲置募 集资金情况，针对投资产品的安全性、期限和收益情况选择合适的产 品。 2、公司财务部将及时与银行核对账户余额，做好财务核算工作， 一旦发现存在可能影响公司资金安全的风险因素将及时采取保全措 施，控制投资风险，并对所投资产品的资金使用和保管进行实时分析 和跟踪。 3、公司内审部门负责投资理财产品与保管情况的审计监督，定 序 号 购买 主体 受托方名称 产品名称 金额 （万 元） 产品 类型 产品起 息日 产品 到期日 预期年 化收益 率 赎回本 金（万 元） 投资收 益（元） 1 湖北多 瑞药业 有限公 司 中国民生银 行股 ...

Key Points - Hainan Huatie's shareholder Hu Danfeng has terminated the share reduction plan and plans to increase holdings in the company with an investment of no less than 30 million yuan and no more than 50 million yuan [2] - Yonghe Co. expects a net profit increase of 447.64% to 506.85% year-on-year for Q3 2025, driven by the high demand in the refrigerant industry and product optimization [3] - Delis Co. is planning a change in company control, leading to a suspension of its stock from October 9, 2025 [4] - BYD reported September 2025 sales of 396,300 new energy vehicles, a slight decrease from 419,400 units in the same month last year, while cumulative sales for the year reached 3.26 million units, up 18.64% [5] - Chipone Technology expects Q3 2025 revenue of 1.284 billion yuan, marking a historical high for the company, with a year-on-year increase of 78.77% [7] - Chipone anticipates a significant improvement in profitability for Q3 2025, with new orders expected to reach 1.593 billion yuan, a year-on-year increase of 145.80% [8] - ST Zhengping's stock will be suspended from trading starting October 9, 2025, due to unusual stock price fluctuations [2][28] - Huanxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [14] - Sichuan Gold won exploration rights for a gold mine in Xinjiang for 510 million yuan, indicating strong geological potential [15]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [4] - Bee Assistant plans to raise no more than 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [5] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Three squirrels have received approval from the China Securities Regulatory Commission for H-share issuance, with plans to issue up to 81.5483 million shares [7] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [8] Group 2 - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind, solar, and energy storage [9] - Sains plans to invest no more than 300 million yuan in the expansion of its selection agent project [10] Group 3 - Hunan YN reports no significant changes in its internal and external operating environment [11] - Electric Power Investment has had its major asset replacement review suspended by the Shenzhen Stock Exchange due to expired financial documents [12] - Guanzhong Ecological is in the planning stage for acquiring a 51% stake in Hangzhou Actuary [13][14] Group 4 - Aima Technology's subsidiary is transferring production capacity and ceasing operations due to strategic adjustments [17] - Fosun Pharma's subsidiary has received approval for clinical trials of a new drug [18] - SAIC Group's subsidiary plans to invest 666 million yuan in the restructuring of SAIC Hongyan [19] Group 5 - Hanwei Technology plans to sell 65% of Hanwei Zhiyuan for approximately 440 million yuan [20] - Xingtong Co. has been awarded new capacity for coastal inter-provincial bulk liquid hazardous goods transportation [21][22] Group 6 - EVE Battery Investment received a cash dividend of 375 million HKD from its associate company [23] - Shanmei International's chairman has resigned due to work changes [24] - Weiye Co.'s chairman has resigned for personal reasons [25] Group 7 - Jiao Da Sino's chairman has been placed under detention [26] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [27][28] - *ST Zhengping's stock has been suspended for investigation due to abnormal price fluctuations [29] Group 8 - Zhenray Technology's chairman has had detention measures lifted [30] - Shiming Technology's chairman has had detention measures changed to a warning [31] - Nanxin Pharmaceutical is under investigation by the CSRC for suspected violations in annual report disclosures [32] Group 9 - Daqian Ecology's shareholder plans to reduce holdings by up to 3% [33] - Rundar Medical's shareholders plan to reduce holdings by up to 2.99% [34][35] - Saili Medical's shareholder plans to reduce holdings by up to 2% [36] Group 10 - Huaxin Environmental plans to repurchase shares for 40 to 80 million yuan [37] - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [38] - Zhongwu Drone has signed a significant contract worth 615 million yuan for drone systems [39]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]